Minomic Archives - We are Minomic

Minomic and Doc Lab at LUGPA 2026 Global Prostate Cancer Congress

by Minomic | Jan 10, 2026

We’re proud to partner with Doc Lab Inc. at the LUGPA 2026 Global Prostate Cancer Congress, where our teams will be exhibiting together in support of advancing prostate cancer diagnostics. 📅 January 10–13, 2026📍 Grand Hyatt Deer Valley | Park City,...

Minomic at JPM Healthcare Week 2026

by Minomic | Dec 30, 2025

Minomic will be in San Francisco during JPM Healthcare Week, connecting with partners and investors through curated forums and 1:1 meetings. We’ll be participating in the QNova LifeSciences JPM Partnering Forum and meeting privately throughout the week to discuss...

Minomic at LUGPA 2025

by Minomic | Nov 6, 2025

Minomic and Doc Lab Inc. are teaming up at LUGPA2025 in Chicago — and we can’t wait to connect with the urology community. We have an 𝐞𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐞𝐯𝐞𝐧𝐭 𝐩𝐥𝐚𝐧𝐧𝐞𝐝 that you won’t want to miss! Be sure to stop by and learn more about how we’re advancing prostate cancer...

Join us for an Educational Dinner Event

by Minomic | Sep 1, 2025

We invite you to an evening of learning and networking as we introduce MiCheck® Prostate — a next-generation blood test designed to help clinicians better identify men at increased risk for clinically significant prostate cancer. 📍 Eddie Merlot’s, 505 Congress Street,...

Doc Lab Partnership Announcement

by Minomic | Aug 24, 2025

We’re thrilled to announce our strategic partnership with Doc Lab Incorporated! Doc Lab has been named a Top 10 Lab Management Company by Med Health. The Game-Changer: Through our collaboration with Doc Lab, MiCheck® Prostate is now available right in your...

Minomic at AUA 2025

by Minomic | Apr 30, 2025

Minomic Inc attended the 120th American Urological Association Annual Meeting in Las Vegas on 26-29 April — a key global gathering for urology leaders and innovators. CEO of Minomic Inc, Sushmita Utpala, had the opportunity to meet with two incredible leaders shaping...

« Older Entries

PUBLICATIONS

Detection of rare prostate cancer cells in human urine offers prospect of non-invasive diagnosis. Sayyadi, N, Justiniano, I, Wang, Y, Zheng, X, Zhang, W, Jiang, L, Polikarpov, DM, Willows, RD, Gillatt, D, Campbell, D, Walsh, BJ, Yuan, J, Lu, Y, Packer, NH, Wang, Y & Piper, JA 2022. Scientific Reports, vol. 12, no. 1, 18452.

Cancer-derived small extracellular vesicles: emerging biomarkers and therapies for pancreatic ductal adenocarcinoma diagnosis/prognosis and treatment. Zhang, W, Campbell, DH, Walsh, BJ, Packer, NH, Liu, D & Wang, Y 2022. Journal of Nanobiotechnology, vol. 20, no. 1, 446.

Phenotypic profiling of pancreatic ductal adenocarcinoma plasma-derived small extracellular vesicles for cancer diagnosis and cancer stage prediction: a proof-of-concept study. Wei Zhang, Ling Wang, Dan Li, Douglas H. Campbell, Bradley J. Walsh, et al. RSC. 2022.

Development and evaluation of the MiCheck test for aggressive prostate cancer. Shore ND, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, et al. Urol Oncol Semin Orig Investig. 2020.

A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population—The MiCheck-01 prospective trial Shore ND, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, et al. Urol Oncol. 2020.

The Role of Glypican-1 in the Tumour Microenvironment. Lund ME, Campbell DH, Walsh BJ. Adv Exp Med Biol. 2020.

Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. Campbell DH, Lund ME, Nocon AL, Cozzi PJ, Frydenberg M, De Souza P, et al. PLoS One. 2018.

Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker. Levin RA, Lund ME, Truong Q, Wu A, Shore ND, Saltzstein DR, et al. Oncotarget. 2018.

Glypican-1 as a biomarker for prostate cancer: Isolation and characterization. Truong Q, Justiniano IO, Nocon AL, Soon JT, Wissmueller S, Campbell DH, et al. J Cancer. 2016.

PATENTS

Minomic Patent Estate